Skip to main content
ARS Home » Southeast Area » Oxford, Mississippi » Natural Products Utilization Research » Research » Publications at this Location » Publication #213657
Title: The Lysosome and HER3 (ErbB3) Selective Anticancer Agent Kahalalide F: Semisynthetic Modifications and Antifungal Lead-Exploration Studies

Author
item SHILABIN, ABBAS GHOLIPOUR - UNIVERSITY OF MISSISSIPPI
item KASANAH, NOER - UNIVERSITY OF MISSISSIPPI
item Wedge, David
item HAMANN, MARK - UNIVERSITY OF MISSISSIPPI

Submitted to: Journal of Medicinal Chemistry
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 2/15/2007
Publication Date: 8/14/2007
Citation: Shilabin, A., Kasanah, N., Wedge, D.E., Hamann, M.T. 2007. The Lysosome and HER3 (ErbB3) Selective Anticancer Agent Kahalalide F: Semisynthetic Modifications and Antifungal Lead-Exploration Studies. Journal of Medicinal Chemistry. 50:4340-4350.

Interpretive Summary: Kahalalide F shows remarkable anti-tumor activity against different carcinomas and has recently completed phase I clinical trials and is being evaluated in phase II clinical studies. In this paper we report on other biological activities of Kahalalide F and several of is analogs. The antifungal activity of Kahalalide F to several plant pathogens was of important significance and herein reported. The Kahalalide F series of compounds was highly active against Fusarium spp. which represents an opportunistic infection in humans and plants.

Technical Abstract: Kahalalide F shows remarkable anti-tumor activity against different carcinomas and has recently completed phase I clinical trials and is being evaluated in phase II clinical studies. The antifungal activity of this molecule has not been thoroughly investigated. In this report, we focused on acetylation and oxidation of the secondary alcohol of threonine, as well as reductive alkylation of the primary amine of ornithine and each product was evaluated for improvements in antifungal activity. Kahalalide F and analogs do not exhibit antimalarial, anti-leishmania, or antibacterial activity, however the antifungal activity against different strains of fungi, was particularly significant. This series of compounds was highly active against Fusarium spp. which represents an opportunistic infection in humans and phytopathogen. The in vitro cytotoxicity for the new analogs of Kahalalide F was evaluated in the NCI 60 cell panel. Analog 5 exhibited enhanced potency in several human cancer cell lines relative to Kahalalide F.